Skip navigation Jump to main navigation

Robert Klitzman on EpiPen's Price Hike

With EpiPen price-gouging in the news, Columbia's School of Professional Studies Bioethics Program Director, Dr. Robert Klitzman, has a new op-ed in CNN about the ethical questions raised by drug companies' overcharging patients. It's a tangled story of the principles of medicine, the profit priorities of private companies, and the taxpayers' money that creates these innovations.

Read the full article at CNN.